With Viking Therapeutic’s (VKTX) recent announcement of Phase 2B Initiative VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) goes hand in hand with the primary endpoint of the study which will evaluate the relative change in liver fat content, as assessed by magnetic resonance imaging, proton density fat fraction (MRI-PDFF), from baseline to Week 12 in subjects treated with VK2809 as compared to placebo.
Secondary objectives include evaluation of histologic changes assessed by hepatic biopsy after 52 weeks of dosing. The trial has received clearance for the first six months of dosing and, subject to submission and satisfactory regulatory review of data from recently completed 12-month toxicity studies, patients will continue to receive VK2809 for the planned 52-week treatment duration.
Based on the latest filings with the SEC, investors are looking at Viking Therapeutics, Inc. (NASDAQ:VKTX)’s short data and trying to figure out market sentiment on which way the market thinks the stock is moving. The firm has 29.56% of total shares float short, yielding a short ratio of 13.19.
As we move into the second half of the year, investors may be wondering what’s in store for stocks. During the summer months, markets are typically a bit more subdued. Investors might be looking to get positioned for whatever is coming. Many feel that the bull market may be losing steam, while others believe that there is plenty of room for the market to cruise higher. Market conditions can change quickly, and being prepared for the worst may help ease the burden if the tide turns unexpectedly.
As we move into the second half of the year, investors may be wondering what’s in store for stocks. During the summer months, markets are typically a bit more subdued. Investors might be looking to get positioned for whatever is coming. Many feel that the bull market may be losing steam, while others believe that there is plenty of room for the market to cruise higher. Market conditions can change quickly, and being prepared for the worst may help ease the burden if the tide turns unexpectedly.
Viking Therapeutics (VKTX) Recommendation
Let’s take a look at how the stock has been performing recently. Over the past twelve months, Viking Therapeutics, Inc. (NASDAQ:VKTX)’s stock was 3.27%. Over the last week of the month, it was 13.59%, 10.49% over the last quarter, and 0.51% for the past six months.
Over the past 50 days, Viking Therapeutics, Inc. stock’s -6.06% off of the high and 30.75% removed from the low. Their 52-Week High and Low are noted here. -27.10% away from the high and 30.75% from the low.
When active traders find an opening to get in on a stock they think is about to make a move, they may try to buy up as much as they can before the price moves back outside the buying range. This buying may be seen when the stock market dips after a bearish move. Spotting these buying conditions and being able to make a timely move can help the trader take advantage of various market scenarios. Winning traders are typically ready to pounce on any opportunity they find in the stock market.
The consensus analysts recommendation at this point stands at 1.50 on Viking Therapeutics, Inc. (NASDAQ:VKTX). This is based on a 1-5 scale where 1 indicates a Strong Buy and 5 a Strong Sell. The same analysts are predicting that the company shares will trade to $23.70 within the next 12-18 months.
While it’s hard finding sleeping giants like this, there’s an opportunity open right now that you can not afford to miss, watch the presentation and get started now.
